Royalty Report: Drugs, Vaccine, Cancer – Collection: 319599

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • Vaccine
  • Cancer
  • Drug Discovery
  • Stem cells
  • Therapeutic
  • Delivery
  • Antibody
  • Disease
  • HIV / AIDs
  • Nanoparticles
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 319599

License Grant
Licensor, one of the nation’s leading research universities in topics such as health sciences, hereby grants to Licensee a limited, transferable (solely to Patriot Scientific or any purchaser of Licensee), exclusive license (referred to as Evaluation License) to evaluate the Materials for use in the Field of Use and to practice any method, process or procedure during the Evaluation Period solely for purposes of the Evaluation. The Evaluation License will terminate upon the expiration or termination of this Agreement, unless extended by mutual agreement. No other evaluation license will be granted in the Field of Use for the Evaluation Period.

Licensor hereby grants to Licensee the exclusive option to enter into a license agreement from Licensor for the commercial development, use, and sale of the Technology, products based on the Technology, patents, trade secrets, know-how, and other information related to the Technology;

License Property
Technology shall mean Materials or any intellectual property developed by Licensee from Materials including without limitation, all or any of the inventions and developments related thereto or arising out of any compositions, data, strains, patent applications, processes, techniques, contained therein and any physical embodiments thereof.

Materials shall mean the materials and/or intellectual property listed
– Licensor IDF Number 2013-2417 entitled “Non-Covalent Loading of Plant Picornavirus Particles” with US Patent Application US2015/0376578 A1 and EP Patent Application 14754692.3
– Licensor IDF Number 2015-2767 entitled “Cancer Immunotherapy using Virus Particles with US Patent Application US2018/0133304 A1 and associated foreign patent applications in Japan, China, Canada, Australia, and EP, US non-published patent application with patent serial number 16/612,214, and PCT Patent application with publication number WO 2018/208828 A1
– Licensor IDF Number 2017-3151 entitled “Melt Processed Viral Nanoparticle Constructs” with US Patent Application US2019/0350871 A1 and EP Patent Application 17868454.4

Patents shall mean any patent that issues or has issued to Licensor or patent application covering or consisting of the Technology and based on intellectual property in existence as of the Effective Date and any related patent or patent application that is a continuation, continuation-in-part, divisional, or reissue in the United States of America or any other country.

Field of Use
The technology is a novel platform technology using virus-like nanoparticles to treat and prevent cancer and infectious diseases in humans and for veterinary use.

The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19.
The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.
This immuno-oncology approach provides a personalized treatment approach by relieving the patient’s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor.

The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.

Field of Use shall mean all therapeutic, diagnostic, vaccine and preventive uses of Technology for both veterinary and human applications. Final field of use, including specific indications, which may be narrower than the Field of Use, will be defined in any commercial use license. Said commercial use license will necessarily incorporate developmental, regulatory, and commercial distribution/sales milestones for each product that incorporates any Technology in the Field of Use. For clarification purposes, Technology and Materials shall not be used in or on humans during the Evaluation Period unless Licensee consults with Licensor regarding appropriate, and possibly expanded, indemnification and insurance requirements and receives Licensor’s written authorization to do so. Such authorization will be in Licensor’s sole discretion.

IPSCIO Record ID: 364016

License Grant
Licensor hereby grants to Licensee an exclusive license, subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.

Licensor also hereby grants to Licensee an exclusive license to make, use, and/or sell the Licensed Materials in the Territory for the Field of Use. At Licensees request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

License Property
Protein GP96 Vaccination (UMD-107) technology is a platform designed to activate immune responses against cancer or infectious diseases.

U.S. patent application serial number US 61/033,425 entitled 'Heat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 20 March 2008;
PCT patent application number PCT/US2009/001727 entitled 'bleat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 19 March 2009;
all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT patent application number PCT/US2009/001727 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.

“Patent Rights” shall mean the following United States Patent applications  U.S. patent application serial number US 61/033,425 entitled “ Allogeneic Cancer Cell-Based Immunotherapy” and files on 3 March 2008; PCT patent application number PCT/US2009/001330 entitled “Allogeneic Cancer Cell-based Immunotherapy” and filed on 3 March 2009; all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT application number PCT/US2009/001330 to meet the requirements of 35 U.S.C. 112¶1; and any re-examination or reissues of the foregoing.

Field of Use
Field of Use is for the treatment of cancer relating to all human healthcare and research applications.

IPSCIO Record ID: 308739

License Grant
University hereby grants to Licensee the exclusive right and license, with the right to sublicense, in the Territory to make, have made, use, sell, and import the Licensed Product in the Field and to practice under the Patent Rights in the Field until the expiration of the last to expire valid claim of the Patent Rights, unless this Agreement is terminated sooner as provided herein.  University reserves the royalty-free, nonexclusive right to practice under the Patent Rights and to use Licensed Product for Non-Commercial Education and Research Purposes.
License Property
Application #06/611,797 – Identification of an IL-13 receptor alpha2 peptide analogue capable of enhancing stimulation of glioma-specific CTL response.

Application #11/231,618 – Peptide Analogs capable of enhancing stimulation of a glioma-specific CTL response.

Patent Rights shall mean University intellectual property described below and assigned to University
(a) The United States and foreign patents and/or patent applications listed;
(b) United States and foreign patents issued from the applications listed and from divisionals, substitutions, continuations and continuation-in-parts of these applications;
(c) United States and foreign patents issued from any of the foregoing, including all reissues, registrations, renewals, reexaminations and extensions thereof; and
(d) Claims of U.S. and foreign continuation and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed.

Field of Use
Field shall mean brain cancer peptide(s) antigen vaccines including systemic use and use in a cell based Peptide antigen vaccine regimen ( excluding cDNA and/or gene therapy based antigen delivery and expression).

Licensee is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.

IPSCIO Record ID: 364010

License Grant
Licensor hereby grants to Licensee and exclusive license. Subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.  

Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use.  At Licensee’s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.

License Property
The Podack Cancer Vaccine (UM97-14) technology shall mean the technology relating to a cell-based vaccine for treating cancer patients utilizes human cancer cells that have been engineered to secrete gp96.  The presently preferred version of the vaccine uses the AD100 human lung adrenocarcinoma cell line transfected with constructs that encode III.A-AI and gp96-Ig (heat shock protein gp96 fused to Fe region of IgGI).  In a presently preferred protocol, NSCLC patients are intradermermally administered several injections of 5×107 vaccine cells each at two week intervals.

Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line “AD100-gp96/III.A”.

Patent Rights shall mean the following United States Patent applications  U.S. provisional patent application serial number 60/075.358 entitled “Modified Heat Shock Protein-antigenic Peptide Complex” and filed on February 20, 1998  U.S. patent application serial number 09 253.439 entitled “Modified Heat Shock Protein-Antigenic Peptide Complex” and filed on February 19, 1999  U.S. patent  application serial number 11/878.460 entitled “Recombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complex” and filed on July 24, 2008  all United States patents and foreign patents and patent applications based on these U.S. applications  all divisionals, continuations of the foregoing  and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358.  U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.  â€œPatent Rights” shall not include Excluded Patent Rights.

Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.

Field of Use
Field of Use is for treating cancer patients and shall mean all human healthcare and research applications.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 280840

License Grant
Licensor hereby grants to Licensee an exclusive license under the Licensed Patents in the Territory to make, have made, develop, use, practice, import, export, distribute, market, promote, offer for sale, and sell Licensed Products in the Licensed Field.

Licensor hereby grants to Licensee a non-exclusive license in the Territory under Licensor’s rights in the Know-How to use and practice any method, process, or procedure within the Know-How and otherwise use and exploit the Know-How; all in the Licensed Field; provided however, that with respect to Project Information, such non-exclusive license shall be limited to the Project Information Licensed Field.

License Property
The technology relates to drugs used in the treatment of various cancers.

Licensed Patents means
Patent Applications 61/249,596; 61/423,842; 61/423,825; 61/392,296; 61/423,832; 61/254,395; 61/423,838

1.
REVERCOM

·
Drug summary Liposome-packaged combination of proprietary molecule, inhibitor of multidrug resistance transporter, and conventional chemotherapeutic agent.

·
Potential use adjuvant applied as part of chemotherapy of cancer patients.

2.
MOBILAN

·
Drug summary Adenovirus-based treatment inducing immune response. Ready for final stage of preclinical development.

·
Potential use Universal anti-cancer vaccine.

3.
ARKIL

·
Drug summary Androgen receptor inhibitor, prepared for Hit-2-Lead optimization studies.

·
Potential use Nanodrugs for treatment of prostate cancer (both hormone (androgen)-dependent and –independent/refractory forms).

4.
ANTIMYCON

·
Drug summary MYC inhibitor.

·
Potential use Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies.

Projects and Licensed Patents
1. Projects

Drug
Definition

Mobilan = Research, development and support of an immunotherapeutic drug candidate based on recombinant adenovirus vector, stimulating immune response in humans as a vaccine-like treatment for cancer or other indications.

Revercom = Research, development, formulation and support of a drug candidate based on proprietary Reversan compound as an adjuvant for chemotherapy.

Antimycon = Research, development, lead optimization, formulation and support of a drug candidate regulating cMyc transcription factor for cancer indications.

Arkil = Research, development, lead optimization, formulation and support of a drug candidate regulating androgen receptor for prostate cancer.

Xenomycin = Research, development, lead optimization, formulation and support of a drug candidates based on proprietary Curaxin family of compounds for anti-infective/anti-biotic/anti-fungal applications.

2. Licensed Patents

Product
Title
Inventors
Country
Application No.
Patent No.

MOBILAN = Use of Toll-Like Receptor and Agonist for Treating Cancer
Andrei Gudkov (RPCI, CBLI)
U.S.
61/249,596
n/a

MOBILAN = Toll-like receptor 5 agonist produced and secreted by mammalian cells
Andrei Gudkov (RPCI), Venkatesh Natarajan (RPCI)
U.S.
61/423,842
n/a

MOBILAN = Functional bacreriophage-based nanoparticles coated by Toll-like receptor 5 agonist
Andrei Gudkov (RPCI, CBLI), Venkatesh Natarajan (RPCI)
U.S.
61/423,825
n/a

ANTIMYCON = Small molecules inhibiting oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
U.S.
61/392,296
n/a

ANTIMYCON = Small Molecules Inhibiting Oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
U.S.
61/423,832
n/a

ARKIL = Method for treating androgen receptor positive cancers
Katerina Gurova (RPCI), Natalia Narizhneva (CBL)
U.S.
61/254,395
n/a

REVERCOM = Dual cargo nanoparticles combining MRP1 inhibitors with chemotherapeutic drugs
Andrei Gudkov (RPCI, CBLI), Aridam Sen (RPCI), Catherine Burkhart (CBLI), Padmaja Kunapuli (RPCI)
U.S.
61/423,838
n/a

Field of Use
“Application” means the intended use for a Licensed Product, including the diagnosing, treating, curing, mitigating, and/or preventing a disease or other condition in a human or other animal, such as small cell lung cancer, large cell lung cancer, or other specific disease state.

IPSCIO Record ID: 329718

License Grant
Licensor hereby grants to Licensee
(A) an exclusive, royalty-bearing right and license, with the right to grant sublicenses as set forth in this Agreement, under the Licensor Technology, the Licensor Collaboration Technology and the Joint Collaboration Technology, in each case solely to  (1) sell, offer to sell, import, use, and otherwise Commercialize Non-Co-Promoted Products (other than MDX-1379) for any purpose in the Field in the United States; and
(2) sell, offer to sell, import, use and otherwise Commercialize Products for any purpose in the Field in the Royalty Territory; including, in each case ((1) and (2)), for use as monotherapy or for use together or in combination with Agents, other Immunotherapeutic Agents, or other vaccines, biologics or compounds; (3) sell, offer to sell, import, use and otherwise Commercialize MDX-1379 for all uses permitted by the PHS License for use in the Field in the Royalty Territory; and (4) make and have made Non-Co-Promoted Products (other than MDX-1379), Products and MDX 1379 for use in the activities set forth in this Agreement.

(B) a co-exclusive (with Licensor and its Affiliates), royalty-bearing right and license, with the right to grant sublicenses as set forth in this Agreement, under the Licensor Technology, the Licensor Collaboration Technology and the Joint Collaboration Technology, in each case solely to (1) sell, offer to sell, import, use and otherwise Commercialize Products (other than Non-Co-Promoted Products) for any purpose in the Field in the United States, including in each case for use as monotherapy or for use together or in combination with each Agent with respect to which the Co-Promotion Product is Developed in accordance with this Agreement; and (2) sell, offer to sell, import, use and otherwise Commercialize MDX-1379 for all uses permitted by the PHS License for use in the Field in the United States (but which license shall be exclusive if MDX-1379 is a Non-Co-Promoted Product); and
(3) make and have made Products and MDX-1379 (other than Non-Co-Promoted Products) for use in the activities set forth in this Agreement.

License Property
MDX-1379 means that certain gp100 peptide vaccine being Developed by Licensor as of the Execution Date for use together, or otherwise in combination, with MDX-010 for the treatment of metastatic melanoma.

MDX-010 is a fully human antibody against human CTLA-4, a molecule on T cells that is believed to be responsible for suppressing the immune response. MDX-010 also has the potential to enable the immune systems of cancer patients to more effectively fight tumors.

Lead Antibody means MDX-010, which has the amino acid sequences for CDR 1, 2 and 3 of the heavy chain variable region as Previously Disclosed.

U.S. Patent No. 5,811,097 – Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
U.S. Patent No. 5,855,887 – Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
U.S. Patent No. 6,051,227 – Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling

Antibody means any antibody, or fragment thereof, whether human, humanized, chimeric, murine or from any other source (and including bispecific antibodies, single chain antibodies, and immunoconjugated antibodies), that (a) has been raised, engineered or otherwise optimized to bind specifically and directly to the Target (whether exclusively or in addition to any other target such Antibody may modulate), and (b) once bound to the Target, has antagonistic activity against or otherwise blocks the immunosuppressive signaling of the Target.  For clarification, (x) any antibody or fragment thereof, whether human, humanized, chimeric, murine or from any other source (and including bispecific antibodies, single chain antibodies, and immunoconjugated antibodies) that is Derived from an Antibody, binds specifically and directly to the Target, and otherwise meets the requirements of clause (b) above, shall be an Antibody for purposes of this Agreement and (y) any fusion protein comprised of a fragment of an Antibody and that uses such fragment in order to bind to the Target shall be considered an Antibody for purposes of this Agreement.  For clarification, the Lead Antibody is an Antibody.  For the avoidance of doubt, those fusion proteins known as CTLA4-Ig and LEA-29Y shall not be considered Antibodies for purposes of this Agreement.

Licensor Non-Collaboration Technology means (a) any and all Information, Materials and inventions (i) conceived, discovered, developed or otherwise made, solely by or on behalf of Licensor or its Affiliates or, to the extent permitted under the applicable sublicense agreement, its sublicensees (other than Licensee and its Affiliates), or (ii) acquired or otherwise used (but only to the extent Controlled) by Licensor or its Affiliates, in each case ((i) and (ii)), after the Execution Date and during the term of this Agreement, that are necessary or reasonably useful in the Development, Commercialization, manufacture or use of MDX-1379, an Antibody, Product or Non-Antibody Substance, whether or not patented or patentable, but excluding any (u) Excluded Technology, (v) Licensor Pre-Existing Technology, (w) Mice-Related Technology, (x) Mice Materials, (y) Collaboration Technology and (z) any Information, Materials and inventions conceived, discovered, developed or otherwise made, by or on behalf of Licensor, its Affiliates or sublicensees in connection with the clinical trials identified in this Agreement, unless and until such activities are set forth in a Global Development Plan and Budget and Licensee reimburses Licensor for Licensee’s share of such Development Costs as provided in this Agreement (collectively, “Licensor Non-Collaboration Know-How”), and (b) Patents and other intellectual property rights with respect to the Information, Materials and inventions described in clause (a) above (collectively, “Licensor Non-Collaboration Patents”); provided, however, upon termination of this Agreement pursuant to this Agreement with respect to a Product or MDX-1379, Licensor Non-Collaboration Technology shall be limited to (1) Licensor Non-Collaboration Know-How and Licensor Non-Collaboration Patents with respect to such Product or MDX-1379 that are in existence as of the date of termination, and (2) those Patents that are filed thereafter to the extent that they claim Licensor Non-Collaboration Know-How included in clause (1) above.  For purposes of this definition, the determination of whether Information, Materials and inventions are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall be made in accordance with Applicable Law in the United States.

Commercialize means to promote, market, distribute, sell (and offer for sale or contract to sell) or provide product support for a Product or MDX-1379.

Field of Use
Field of use is for the treatment of metastatic melanoma (cancer) by the development and commercialization of an antibody-based product incorporating MDX-010 as the sole active ingredient or for use together, or otherwise in combination, with MDX-1379 (gp-100) or with certain other immunotherapeutic agents. The Lead Product is for use in the first Cancer Indication.

Cancer means any type of cancer in any cell or organ in a human body, including any Core Cancer.

IPSCIO Record ID: 371191

License Grant
The Company holds an exclusive, worldwide license from the Licensor, a British university technology transfer and consultancy company, to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products in accordance with its development plan.
License Property
The patent, United States Patent No. 11,123,442, includes claims directed to specific compositions of polypeptides, or epitopes of limited variability, and methods of treating influenza infection with the compositions.

Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology.  Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection.   Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.

Field of Use
The Company is currently developing a universal influenza vaccine and an H1N1 vaccine candidate that both utilize the epitopes of limited variability that are covered in the patent.

Field of use is for the treatment of influenza.

IPSCIO Record ID: 330686

License Grant
The agreement grants rights to Licensee to patents and intellectual property, solely to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process into and throughout the Territory for research and development of Companion Diagnostics.

Also included is a grant back If this Licensor desires to develop, manufacture, exploit, import, use, offer for sale or sell any Companion Diagnostic on its own or with or through any Affiliate or Third Party, it will send written notice thereof to Licensee, and, if Licensee chooses not to develop, then Licensor shall be granted any associated rights to do so.

License Property
The licensed technology includes (I) Alternative Splicing Event (ASE) technology based on International Patent Application WO 2012/116248 A1 entitled 'Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers'; and (ii) Technology and know-how stemming.

Companion Diagnostics means any diagnostic product or biomarker arising from work performed by Licensor pursuant to the terms of this Agreement or otherwise derived from or based in whole or in part on Licensees Intellectual Property.

Discovery Product means a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.

Therapeutic Product means an agent with prophylactic or therapeutic activity for the prevention and/or treatment of cancer, developed, in whole or in part, from a Discovery Product and intended to be used, or is used, to treat cancer in humans.

Licensee Patent Rights include
– FGFR1/2 IIIc in NSCLC resistant to erlotinib.
– FGFRviii in glioblastoma.

MIT Patent Rights include
– Alternatively Spliced mRNA lsoforms as Prognostic Indicators for Metastatic Cancer.

Field of Use
Field means the use or intended use in treatment and/or prevention of cancer in humans, and shall include the use of any Licensed Product or Licensed Process in connection with the development of Companion Diagnostics.

Licensees therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer.

IPSCIO Record ID: 257492

License Grant
Pursuant to the Agreement, Licensee obtained an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed Products in the Territory.

With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.

As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.

Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.

Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.

License Property
This amendment includes Amended Definitions Relating to Cancer targets, and, Licensed Product means a bulk or finished AIDS Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the research collaboration program; and upon the exercise of an Option for a Cancer vaccine, such bulk or finished Cancer vaccine for the prevention of Cancer Indications, provided, however, that if any vaccine is also capable of being used for treatment of the same human infectious disease or Cancer indication, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement; and Treatment vaccines.

Treatment vaccines means a bulk or finished vaccine.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-1 in humans;  Hepatitis Virus (HBV) and or diseases caused by infection with HBV in humans; and Cancer vaccines for the treatment, but not prevention or prevention and treatment, of Cancer Indications.

IPSCIO Record ID: 243496

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, an exclusive, irrevocable, perpetual, license, with the right to grant sublicenses, under the Assigned Technology to Develop, Manufacture, Commercialize, make, have made, use, have used, offer for sale, sell, have sold and import Covered Products in the Licensee Field in the Territory.

Assignment; License-Back.  Licensee hereby assigns, transfers, conveys and delivers to Licensor, and Licensor hereby accepts all and every right, title and interest of Licensee in and to the Licensee Patent Rights listed, together with all ancillary rights thereto, including the right to sue for damages by reason of past infringement of any such rights; and the Licensee Intellectual Property owned by Licensee that relates directly to such Licensee Patent Rights (collectively, the Assigned Technology).

License Property
Intellectual property relates to superentolimod product candidate and entolimod vaccine product candidate.

Covered Product(s) means any product the Development, Manufacture, use or sale of which is covered by the Licensee Patent Rights or makes use of any Licensee Intellectual Property.

Patent Rights means any and all (a) issued patents and (b) pending patent applications, including all provisional applications, substitutions, divisionals, continuations, continuations-in-part, renewals, and all letters of patent granted with respect to any of the foregoing, (c) patents of addition, restorations, reissues, extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-examinations; (d) inventor’s certificates; and (e) other forms of government issued rights substantially similar to any of foregoing, in each any country in the Territory.

Licensee Intellectual Property means Know-How that is Controlled by Licensee or its Affiliates during the term of this Agreement and that is reasonably necessary or useful for or directly related to the Development, Manufacture or Commercialization of the Covered Products. The term Licensee Intellectual Property does not include (a) any Know-How, which is, as of the Effective Date or later becomes, generally available to the public, excluding Licensee Confidential Information or Know-How Controlled by Licensee or its Affiliates that is publicly disclosed by a Third Party without the consent of Licensee, and Know-How included in Licensee Patent Rights

Licensee Patent Rights means those Patent Rights that Cover Licensee Intellectual Property and are Controlled by Licensee or its Affiliates at any time during the term of this Agreement.  Licensee Patent Rights as of the Effective Date are listed which shall be updated in writing from time to time, at least annually, during the term of this Agreement.

Title Flagellin compositions
Jurisdiction USA
Application Detials 15/329,870, Filing Date 07-29-2015, Priority Date 07-30-2014
Patent Details N/A
Status Pending

Title  Flagellin compositions and uses including effective vaccination
Jurisdiction  USA
Application Details  15/500,133, Filing Date 07-30-2015, Priority Date 07-30-2014
Patent Details  N/A
Status  Pending

Field of Use
Licensor Field means the prevention or treatment of any disease or condition in humans that is caused by the recent exposure to ionizing radiation including mitigation and prevention of Acute Radiation Syndrome (as defined by the Center for Disease Control and Prevention) and concurrent radiation treatment of humans or animals diagnosed with oncological conditions at the time of treatment to treat this condition. For the avoidance of doubt, it is understood and agreed that the Licensee Field shall not include (i) prevention or treatment of sickness, diseases, disorders, and frailties caused by prior exposure to radiation treatment of cancer, and (ii) prevention or treatment of any disease, disorder or frailty in humans that are “cancer survivors” (i.e., persons who has completed initial cancer management and has no apparent evidence of active disease).

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 304223

License Grant
University granted to the Company an exclusive license for certain inventions and technologies related to nanoparticles useful as vaccines.
License Property
The University has developed certain inventions and technology related to nanoparticles.

The Inventions and Technologies licensed relate to the ABBIE patent estate that includes patent families.  One such family is titled “Novel Nanoparticle–Based Vaccine Targeting Cancer/Testis Antigens (CTA) and its’ Use in Solid and Hematological Malignancies”.  The use and methods for a vaccine composition comprising of particles comprising nanoparticles, microparticles or a mixture thereof.

ABBIE is a non-viral gene editing mechanism to insert the target DNA template information into the T cell genome at a precise, predetermined locus. ABBIE allows the creation of the plasmid (“glue”) that goes through the membrane to the nucleus and inserts the genome template into the T cells so that they could express the CAR T protein and possibly other accessory proteins while possibly eliminating unwanted inhibitory proteins.

Field of Use
Licensee is a target discovery and gene editing company utilizing artificial intelligence and their proprietary neural network platform with a therapeutic focus on immuno-oncology.

The license granted is for the inventions and technologies for the use of oral vaccines for any diseases, including, without limitation, any form of cancer.

IPSCIO Record ID: 345562

License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2.  This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.

ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.

Field of Use
Field of use is for the immunotherapy and vaccine fields.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.